. 2017 Sep 22;90(1):109–119. doi: 10.1002/jmv.24923

Table 1.

SVR rates by HCV GT2 subtype in Japanese studies M12‐536 and GIFT‐II

Study	Subgroup	Subtype	SVR rate, % (n/N) ^a	Number of VFs ^b
M12‐536 ^c	25/100/100 mg	2a	81.8 (9/11)	2
		2b	14.3 (1/7)	6
	25/150/100 mg	2a	100 (9/9)	0
		2b	37.5 (3/8)	5
GIFT‐II ^d	12 wk, TN, non‐cirrhotic	2a	82.8 (24/29)	3
		2b	63.2 (12/19)	7 ^e
	12 wk, TE, non‐cirrhotic	2a	86.4 (19/22)	3
		2b	22.2 (2/9)	7
	12 wk, cirrhotic	2a	100 (3/3)	0
		2b	50 (1/2)	1
	16 wk, TN, non‐cirrhotic	2a	93.9 (31/33)	2
		2b	85.7 (12/14)	2
	16 wk, TE, non‐cirrhotic	2a	93.8 (15/16)	1
		2b	56.3 (9/16)	6
	16 wk, cirrhotic	2a	50 (1/2)	0
		2b	25 (1/4)	3

SVR, sustained virologic response; TN, Treatment‐naïve; TE, Treatment‐experienced to an IFN‐containing regimen with or without RBV; VF, virologic failure.

^{^a}

% of patients achieving SVR₁₂ in study GIFT‐II,20 or SVR₂₄ in study M12‐536.7

^{^b}

Number of patients who experienced virologic failure. Excludes patients who did not achieve SVR due to non‐virologic reasons such as premature study drug discontinuation or missing SVR₁₂ or SVR₂₄ data.

^{^c}

Patients in study M12‐536 received OBV/PTV/r for 12 weeks, and all patients were treatment‐experienced to pegIFN/RBV and were non‐cirrhotic.

^{^d}

GIFT‐II treatment regimen included co‐formulated ombitasvir/paritaprevir/r (25/150/100 mg QD) + RBV for 12 or 16 weeks. Patients were treatment naïve or treatment‐experienced to an IFN containing regimen (IFN alpha, beta, or pegIFN) with or without RBV.

^{^e}

One GT2b‐infected treatment‐naïve patient achieved SVR₁₂ but relapsed at PTW24.